Evaluation of Efficacy of Lumbar Plexus Bloc After Hip Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00150865|
Recruitment Status : Completed
First Posted : September 8, 2005
Last Update Posted : November 1, 2017
Compare lumbar plexus block with ropivacaine 0.475%, 0.4 ml/kg to saline. Each group randomized, includes 30 patients. block performed preoperatively Surgery under general anesthesia. Postoperative evaluation of pain (VAS) as first endpoint, and also morphine consumption via PCA device. Follow-up : 24h.
Expectation : sizeable reduction of pain with block, of duration.
|Condition or disease||Intervention/treatment|
|Pain Postoperative||Drug: ropivacaine|
Compare lumbar plexus block (randomized)
- ropivacaine 0.475%, 0.4 ml/kg
- saline 0.4 ml/kg . Each group includes 30 patients.
Block performed preoperatively.
Surgery under general anesthesia (sufentanil, propofol, atracurium ; maintenance : sevoflurane and nitrous oxide in O2. Sufentanil added peroperatively as clinically needed.
Postoperative evaluation of pain (VAS, by an independant blind observer) as first endpoint, and also morphine consumption via PCA device.
Adverse effects (nausea, vomiting, etc) recorded
Follow-up : 24h. Expectation : sizeable reduction of pain with block, of duration.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Study of Posterior Lumbar Plexus Block for Pain Relief After Hip Surgery|
|Study Start Date :||September 2001|
|Estimated Study Completion Date :||March 2002|
- decrease of postoperative pain
- decrease in morphine consumption
- duraration of analgesic effect
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00150865
|Study Director:||laurent beydon, MD||University Hospital, Angers|
|Principal Investigator:||ibrahim okais, MD||Clinique St Leonard|